Drug Trial Radar · NCT00842530
Efficacy and Safety of Dengue Vaccine in Healthy Children
Last checked: Nov 19, 2026Latest source record: Apr 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,002
Actual
Start
Feb 2009
Primary completion
Sep 2013
Study completion Feb 2014
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 12, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 4 years, up to 11 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study was to assess the efficacy of CYD dengue vaccine after three injections in preventing symptomatic virologically-confirmed dengue (VCD) cases, regardless of the severity, due to any of the four serotypes in children aged 4 to 11 years at the time of inclusion. Secondary objectives included to assess: * Vaccine efficacy against severe VCD cases * Vaccine efficacy against VCD cases following at least two injections with CYD dengue vaccine * Immune response to CYD dengue vaccine * Safety profile of CYD dengue vaccine. Safety assessments include solicited reactions within 7 or 14 days after each injection, unsolicited adverse events within 28 days after each injection, and serious adverse events during the study period. Other objectives included: * Vaccine efficacy against VCD cases following at least one injection with CYD dengue vaccine * Vaccine efficacy against VCD cases due to each serotype * Participants with clinical signs and symptoms for VCD
Conditions
- Dengue Virus
- Dengue Fever
- Dengue Hemorrhagic Fever
- Dengue Diseases
Interventions
CYD Dengue VaccineBiological
0.5 mL, Subcutaneous
Inactivated rabies virus vaccineBiological
0.5 mL, Subcutaneous
PlaceboBiological
Sodium chloride 0.9%
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Symptomatic Virologically-Confirmed Dengue (VCD) Cases During the Active Phase Post-dose 3 Following Inj. With Either CYD Dengue Vaccine or a PlaceboTime frame: 28 days Post-Inj. 3 up to the end of Active Phase (up to 13 months Post-Inj. 3, i.e. up to 25 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sanofi Pasteur Investigational Site
Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.